Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 11/20 | 0.61 |
| ▸ | FLT4 | P35916 | 11/20 | 0.61 |
| ▸ | KDR | P35968 | 11/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10399038 | 0.86 | ALDH1A1 (0.57) | FLT1FLT4KDREGFRERBB2 | |
| SCHEMBL9526916 | 0.83 | KMT2A (0.69) | EGFRALDH1A1LMNANFKB1SMN1; SMN2 | |
| SCHEMBL11853703 | 0.83 | FLT1 (0.54) | FLT1FLT4KDREGFRERBB2 | |
| SCHEMBL6495011 | 0.83 | STS (0.61) | FLT1FLT4KDREGFRERBB2 | |
| SCHEMBL9128141 | 0.83 | SMN1; SMN2 (0.58) | FLT1FLT4KDREGFRERBB2 | |
| Asulam SCHEMBL64856 | 0.81 | SMN1; SMN2 (0.68) | ALDH1A1LMNATSHRCYP2C19SMN1; SMN2 | |
| Asulam SCHEMBL16899633 | 0.81 | SMN1; SMN2 (0.68) | ALDH1A1LMNATSHRCYP2C19SMN1; SMN2 | |
| SCHEMBL26282718 | 0.81 | MMP2 (0.65) | FLT1FLT4KDREGFRERBB2 | |
| SCHEMBL3805836 | 0.81 | CA1 (0.55) | ALDH1A1LMNATSHRNFKB1SMN1; SMN2 | |
| SCHEMBL13329865 | 0.81 | CA1 (0.59) | EGFRERBB2L3MBTL1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250197359-A1 | CANNABINOID RECEPTOR MODULATING COMPOUNDS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025040089-A1 | NOVEL HETEROCYCLIC COMPOUND FOR SELECTIVELY REGULATING CANNABINOID CB1 FUNCTION | 德睿智药(苏州)新药研发有限公司 | 2025-02-27 | — | — | WO | disclosed |
| US-20250049736-A1 | SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4504179-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | Corbus Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250042861-A1 | TETRAHYDROPYRIDAZINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK A/S (DK) | 2025-02-06 | — | — | US | disclosed |
| EP-4493547-A1 | CANNABINOID RECEPTOR MODULATING COMPOUNDS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-3423448-B1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | US HEALTH (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4448491-A2 | N-((ADAMANTAN-1-YL)CARBAMOYL)-BENZENESULFONAMIDE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPERTENSION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448497-A1 | TETRAHYDROPYRIDAZINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-10-23 | — | — | EP | disclosed |
| EP-1373216-B1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| US-20040248944-A1 | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-12-09 | — | — | US | disclosed |
| EP-1429761-A1 | NOVEL 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-06-23 | — | — | EP | disclosed |
| EP-1373216-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003026647-A1 | NOVEL 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-04-03 | — | — | WO | disclosed |
| EP-1268435-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB 1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2003-01-02 | — | — | EP | disclosed |
| US-6476060-B2 | DRUG ABUSE; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; CARDIOVASCUALR DISORDERS | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2002-11-05 | — | — | US | disclosed |
| WO-2002076949-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2002-10-03 | — | — | WO | disclosed |
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2001-12-20 | — | — | US | disclosed |
| WO-2001070700-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248944-A1 | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | CNR1, CNR2, GPR55 | FLT1 3404/4885FLT4 2932/4885KDR 2724/4885 |
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR1, CNR2, CBR3 | FLT1 2175/4885FLT4 1875/4885KDR 2135/4885 |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | FLT1 2150/4885FLT4 2365/4885KDR 1578/4885 |
| US-20250049736-A1 | SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, FAAH, ECE1 | FLT1 794/4885FLT4 1180/4885KDR 1971/4885 |
| US-20250042861-A1 | TETRAHYDROPYRIDAZINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, TAAR5 | FLT1 2171/4885FLT4 3026/4885KDR 2123/4885 |
| US-20250197359-A1 | CANNABINOID RECEPTOR MODULATING COMPOUNDS | CNR1, CNR2, GPR18 | FLT1 1741/4885FLT4 1491/4885KDR 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.